semaglutide glasgow The Scottish Medicines Consortium (SMC) has accepted Wegovy for use to reduce the risk of major cardiovascular events New hope' for thousands of

1 Introduction Parkinsons disease (PD) is the second most common chronic neurodegenerative disorder (NBD) after Alzheimers disease (AD), with a progressive loss of motor, cognitive, and autonomic (Poewe et al., 2017)

Similar content being viewed by others Article Open access09 October 2023 GLP-1-based therapies for diabetes, obesity and beyond Article 25 April 2025 Article Open access13 February 2025 Introduction In recent years, GLP-1R and its agonists have garnered widespread attention in the medical community

GLP-1 agents demonstrate 15-22% reduction over 68 weeks in trials (tirzepatide) and 10-15% over similar periods (semaglutide)

It is also closely associated with physiological functions

These have specificities for cationic residues (arginine and lysine) and aromatic residues respectively, so that most therapeutic proteins are vulnerable to attack by one or both of these enzymes